370 related articles for article (PubMed ID: 16289868)
1. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease.
Armentero MT; Fancellu R; Nappi G; Bramanti P; Blandini F
Neurobiol Dis; 2006 Apr; 22(1):1-9. PubMed ID: 16289868
[TBL] [Abstract][Full Text] [Related]
2. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
3. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
[TBL] [Abstract][Full Text] [Related]
4. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats.
Breysse N; Amalric M; Salin P
J Neurosci; 2003 Sep; 23(23):8302-9. PubMed ID: 12967992
[TBL] [Abstract][Full Text] [Related]
5. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
[TBL] [Abstract][Full Text] [Related]
6. Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats.
Alam M; Danysz W; Schmidt WJ; Dekundy A
Toxicol Appl Pharmacol; 2009 Oct; 240(2):198-207. PubMed ID: 19616571
[TBL] [Abstract][Full Text] [Related]
7. Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease.
Phillips JM; Lam HA; Ackerson LC; Maidment NT
Eur J Neurosci; 2006 Jan; 23(1):151-60. PubMed ID: 16420425
[TBL] [Abstract][Full Text] [Related]
8. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
Huang KX; Bergstrom DA; Ruskin DN; Walters JR
Synapse; 1998 Sep; 30(1):18-29. PubMed ID: 9704877
[TBL] [Abstract][Full Text] [Related]
9. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
Marin C; Bonastre M; Aguilar E; Jiménez A
Synapse; 2011 Oct; 65(10):1080-6. PubMed ID: 21484883
[TBL] [Abstract][Full Text] [Related]
10. Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions.
Blandini F; Greenamyre JT; Fancellu R; Nappi G
Neurol Sci; 2001 Feb; 22(1):49-50. PubMed ID: 11487196
[TBL] [Abstract][Full Text] [Related]
11. Dizocilpine maleate, MK-801, but not 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline, NBQX, prevents transneuronal degeneration of nigral neurons after neurotoxic striatal-pallidal lesion.
DeGiorgio LA; DeGiorgio N; Volpe BT
Neuroscience; 1999 Apr; 90(1):79-85. PubMed ID: 10188935
[TBL] [Abstract][Full Text] [Related]
12. Blockade of NMDA receptors by MK-801 reverses the changes in striatal glutamate immunolabeling in 6-OHDA-lesioned rats.
Robinson S; Krentz L; Moore C; Meshul CK
Synapse; 2001 Oct; 42(1):54-61. PubMed ID: 11668591
[TBL] [Abstract][Full Text] [Related]
13. Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease.
Orieux G; Francois C; Féger J; Yelnik J; Vila M; Ruberg M; Agid Y; Hirsch EC
Neuroscience; 2000; 97(1):79-88. PubMed ID: 10771341
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
Maranis S; Stamatis D; Tsironis C; Konitsiotis S
Eur J Pharmacol; 2012 May; 683(1-3):71-7. PubMed ID: 22410193
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors.
Lea PM; Movsesyan VA; Faden AI
Br J Pharmacol; 2005 Jun; 145(4):527-34. PubMed ID: 15821750
[TBL] [Abstract][Full Text] [Related]
16. Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats.
Marti M; Sbrenna S; Fuxe K; Bianchi C; Beani L; Morari M
Eur J Neurosci; 2000 May; 12(5):1848-50. PubMed ID: 10792462
[TBL] [Abstract][Full Text] [Related]
17. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons.
Chen L; Zhang QJ; Liu J; Wang S; Ali U; Gui ZH; Wang Y
Brain Res; 2009 Aug; 1286():192-200. PubMed ID: 19545547
[TBL] [Abstract][Full Text] [Related]
18. Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats.
Périer C; Marin C; Jimenez A; Bonastre M; Tolosa E; Hirsch EC
J Neurochem; 2003 Sep; 86(6):1328-37. PubMed ID: 12950442
[TBL] [Abstract][Full Text] [Related]
19. Blockade of mGluR5 reverses abnormal firing of subthalamic nucleus neurons in 6-hydroxydopamine partially lesioned rats.
Chen L; Liu J; Ali U; Gui ZH; Wang Y; Wang T; Hou C; Fan LL
Chin J Physiol; 2011 Oct; 54(5):303-9. PubMed ID: 22135908
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
